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Prevalence of epilepsy in China between 1990 
and 2015: A systematic review and meta–analysis
Background Epilepsy is a major neurological disorder that affects 
approximately 65 million people worldwide. Globally, the burden 
of epilepsy is not evenly distributed, with more than 80% of suffer-
ers residing in low– and middle–income countries. This study esti-
mates the burden of epilepsy in mainland China from 1990 to 2015 
and explores the variations of burden by age and gender.
Methods We conducted a systematic review of the peer–reviewed 
literature from 1990 to 2015 using Chinese and English academic 
databases (CNKI, WanFang, VIP and PubMed) to identify popula-
tion–based prospective studies on the prevalence of epilepsy in 
mainland Chinese. Multilevel mixed–effects logistic regression was 
used to estimate the prevalence of lifetime epilepsy (LTE), and re-
stricted cubic regression splines were applied to model the func-
tional forms of the non–linear effects of age and LTE prevalence. 
Random–effects meta–analysis was used to obtain the pooled prev-
alence of 1–year active epilepsy (AE), 2–year AE and 5–year AE sep-
arately. To estimate the number of people with LTE and AE in the 
years 1990, 2000, and 2015, LTE and AE prevalence were multi-
plied by the total population of mainland China of the correspond-
ing year.
Findings Analyses were conducted using 39 prevalence studies that 
met the inclusion criteria and comprised 77 separate data points (37 
on LTE, 16 on 1–year AE, 12 on 2–year AE and 12 on 5–year AE). 
In 1990, the prevalence of LTE ranged from 1.31‰ (95% CI = 0.85–
2.00) in the 0–4 age group to 2.42‰ (95% confidence interval 
CI = 1.60–3.65) in the 30–34 age group. By 2015, the LTE preva-
lence had increased to 4.57‰ (95% CI = 2.52–8.27) in the 0–4 
group and 8.43‰ (95% CI = 4.71–15.04) in the 30–34 group. Over 
the 25–year period, the overall prevalence of LTE had steadily in-
creased by 259%, from 1.99‰ (95% CI = 1.31–3.02) in 1990 to 
7.15‰ (95% CI = 3.98–12.82) in 2015. The rates of increase were 
similar across the whole age spectrum, fluctuating around 250%. 
Between 1990 and 2015, the total number of people with LTE in 
mainland China increased by 328%, from 2.30 million (95% 
CI = 1.51–3.49) in 1990 to 9.84 million (95% CI = 5.48–17.64) in 
2015. The pooled 1–year, 2–year, and 5–year AE prevalence were 
3.79‰ (95% CI = 3.31–4.34), 4.08‰ (95% CI = 3.41–4.89) and 
4.19‰ (95% CI = 3.42–5.15).
Conclusions The burden of LTE in China has increased substan-
tially between 1990 and 2015, with the prevalence of LTE having 
more than doubled and the number of people with LTE more than 
tripled. The large amount of AE cases in China calls for optimal man-
agement and treatment. More high–quality epidemiological studies 
on LTE and AE prevalence are still needed.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Prevalence of epilepsy in China between 1990 and 2015
Epilepsy is a disorder of neuronal excitability, characterised predominantly by unpredictable and recur-
rent seizures of cerebral origin [1]. As one major neurological disorder, epilepsy affects approximately 65 
million people worldwide, ranging from neonates to elderly [2–5]. The burden of epilepsy is not only 
limited in neurological deficits but also includes devastating psychological and psychiatric problems [6,7], 
influencing the quality of personal, familial and social life significantly [6,8,9]. If left untreated, epilepsy 
would be incapacitating and sometimes fatal. People living with epilepsy generally have higher disability 
and mortality rates [5,10,11]. Worldwide, it is estimated that mortality in people with epilepsy is two to 
three times higher than in the general population [12], while the Global Burden of Disease (GBD) study 
for 2013 estimated the disability–adjusted life year for epilepsy to be 253 per 100 000 people [13,14]. 
Although effective and cost–effective medications exist for controlling seizures, many people with epi-
lepsy are excluded from treatments due to cultural, economic and other factors [11,15]. The global bur-
den of epilepsy is not distributed evenly, with more than 80% of people with epilepsy residing in low– 
and middle–income countries (LMICs) [4,16], where the majority of people with epilepsy receive 
inadequate treatment and management [9,16].
Quality epidemiological data are crucial for estimating the burden of epilepsy which in turn serve to in-
form policies on resource allocation and disease management [17,18]. Over the past decades, the number 
of prevalence studies on epilepsy has grown considerably, making it possible to synthesise prevalence of 
epilepsy at a regional and global level [10,19–24]. Such estimates are valuable despite potential confound-
ers that arise with the difference in sampling, case definitions, case ascertainments, and screening tools 
[10,21,23]. The prevalence estimates of epilepsy in developed countries are generally consistent with each 
other, whereas those in developing countries are often made for isolated geographical areas and they vary 
widely [10,22,23]. It is estimated that the prevalence of epilepsy in LMICs is twice as high as in high–in-
come countries (HICs), making it an even more important global health issue in these settings [16,25].
Nevertheless, the reported prevalence of epilepsy is likely to be conservative, because underdiagnosis and 
misdiagnosis are common in resource–poor areas [10,25]. Furthermore, as a disease marked with stigma 
and prejudice across the world and throughout history, epilepsy may be largely concealed because of pro-
found cultural and social restrictions [7,8,26]. The number of high–quality studies regarding the epide-
miology of epilepsy in the developing world is quite small, which makes the estimate of epilepsy preva-
lence very difficult [10].
In China, although substantial economic development and improvement of health services occurred in 
the past decades, the diversity of development and demographic structures across the whole country still 
limits the opportunity for an estimate of epilepsy prevalence at the national level [19,27]. However, the 
large volume of data on the prevalence of epilepsy in Chinese bibliographical databases makes it feasible 
to explore the burden of epilepsy from a modelling approach [28,29]. For instance, Lian Gu and col-
leagues revealed an overall epilepsy prevalence of 2.89‰ in Mainland China by using the meta–analysis 
method [19]. However, no temporal trend has been analysed in their study, and the prevalence estimates 
were not conducted in a large age span, which may have limited their study to some extent. Moreover, 
as new evidence continues to emerge, such evidence synthesis should ideally be updated using a more 
detailed approach. For these reasons, we conducted a systematic review of the literature in both Chinese 
and English databases to analyse the temporal distribution of epilepsy prevalence in China from 1990 to 
2015. We also investigated the variations in prevalence by age and gender.
METHODS
Literature search
We conducted a parallel systematic review of the published literature from 1990 to 2015 using PubMed 
and three Chinese databases; China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta–Analyses (PRISMA) 
Guidelines and the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) state-
ment [30,31]. The search strategy for PubMed was ((epilepsy) AND (China OR Chinese) AND (inciden* 
OR prevalen* OR morbidity OR mortality)). The search terms for the Chinese databases were the term 
epilepsy in both China and English, and two versions of Chinese terms for ‘incidence’ and ‘prevalence’, 
attack rate, mortality, fatality, epi*, burden, epidemiological survey and cross–sectional investigation. The 
precise combination of the search term for the four databases search is detailed in Table S1 in the Online 
Supplementary Document.
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Selection criteria
Our inclusion criteria were: (1) population–based studies; (2) studies of mainland Chinese populations 
in mainland China; (3) studies that provide prevalence of lifetime epilepsy (LTE) and/or active epilepsy 
(AE); (4) studies that include clear case definitions (the case definitions used to define a case of epilepsy 
are described in detail in Table S2  in Online Supplementary Document). Our exclusion criteria were: 
(1) case–control and hospital–based studies; (2) studies of populations outside of mainland China (in-
cluding Hong Kong and Taiwan); (3) studies of specific areas; eg, mining or fishery districts; and (4) re-
views and conference abstracts; (5) duplicate publications; (6) studies that included febrile convulsions 
and provoked seizures in their estimates of epilepsy prevalence; (7) studies with unclear case definitions; 
and (8) studies with inconsistent results.
Data extraction
Data were independently extracted (PS, YZ and XY for data in Chinese; PS, KYC and AP for data in Eng-
lish). A database was set up to record the extracted information which included names of authors, pub-
lished year, study setting (urban and/or rural), medium year of data collection, sampling method, case 
definition, sample size, number of epilepsy cases, and epilepsy prevalence.
In epidemiological studies of epilepsy, the prevalence estimates of LTE and AE are generally reported sep-
arately, where the LTE prevalence is the proportion of individuals manifesting a disorder anytime during 
the earlier period of their life up to the point of investigation [32], and AE prevalence represents the pro-
portion of individuals who have experienced at least two unprovoked seizures within a certain period of 
time (1 year, 2 years, and 5 years) up to the point of investigation [2,10,33,34]. In data extraction pro-
cess, prevalence estimates were classified into these two exclusive groups based on the definitions or in-
vestigation methodologies provided in each study.
Statistical analysis
Our analysis of epilepsy prevalence was conducted for LTE, 1–year AE, 2–year AE and 5–year AE sepa-
rately. For studies that provided estimates of LTE prevalence, multiple data points were available in each 
study to contribute to the overall database. To take into account the availability of different data points 
from the same study, meta–analysis via multilevel mixed–effects models was adopted [35]. To investigate 
whether LTE prevalence varied significantly according to different demographic factors (age and gender) 
or had a secular trend (study year), univariate meta–regression was adopted to test their significance con-
secutively. Restricted cubic regression splines were used to model the functional forms of the non–linear 
effects of age and LTE prevalence. Variables that significantly correlated with LTE prevalence in the uni-
variate analyses were then included in the final multivariate regression model. Due to the paucity of stud-
ies that reported AE prevalence, effects of demographic factors and secular trends could not be explored 
using meta–regression. Instead, random–effects meta–analysis (DerSimonian Laird method) was applied 
to obtain the pooled prevalence [36].
To estimate the number of people with LTE and AE in the years 1990, 2000 and 2015, LTE and AE prev-
alence were multiplied by the population of China in the corresponding years using population data from 
the United Nations Population Division (UNPD) [37]. All the analyses were conducted in R v3.3.0 (R 
Development Core Team; http://www.R–project.org).
RESULTS
Systematic review
Our database searches returned 17 796 titles. After removing 8100 duplicates, and 9010 titles and ab-
stracts that contained no information on epilepsy prevalence, and 47 papers with insufficient information 
on methods and results, 639 full–text papers were reviewed. Of the 39 full–text papers that met our in-
clusion criteria, 37 reported LTE prevalence, 16 reported 1–year AE prevalence, 12 reported 2–year AE 
prevalence and 12 reported 5–year AE prevalence (Figure 1).
Study characteristics
Table 1 summarises the key characteristics of the 39 studies. All studies were cross–sectional in design. 
Most of them were large studies published after 2000. Participants were typically investigated by neurol-
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Table 1. Main characteristics of the retained studies
CharaCteristiCs of study studies with Lte preva-
LenCe (n = 37, %)
studies with 1–year ae 
prevaLenCe (n = 16, %)
studies with 2–year ae 
prevaLenCe (n = 12, %)
studies with 5–year ae 
prevaLenCe (n = 12, %)
Year published:
1990–1999 12 (32.4) 0 (0.0) 0 (0.0) 0 (0.0)
2000–2009 16 (43.2) 11 (68.8) 8 (66.7) 7 (58.3)
2010–2016 9 (24.3) 5 (31.3) 4 (33.3) 5 (41.7)
Setting:
Urban 4 (10.8) 1 (6.3) 1 (8.3) 1 (8.3)
Rural 21 (56.8) 14 (87.5) 10 (83.3) 10 (83.3)
Mixed 9 (24.3) 1 (6.3) 1 (8.3) 1 (8.3)
Both 3 (8.1) 0 (0.0) 0 (0.0) 0 (0.0)
Sample size:
4000–10 000 9 (24.3) 2 (12.5) 1 (8.3) 1 (8.3)
10 001–50 000 17 (45.9) 11 (68.8) 9 (75.0) 10 (83.3)
50 001–200 000 8 (21.6) 2 (12.5) 2 (16.7) 1 (8.3)
200 001–900 000 3 (8.1) 1 (6.3) 0 (0.0) 0 (0.0)
Screening tool:
WHO questionnaire 14 (37.8) 9 (56.3) 7 (58.3) 7 (58.3)
ICBERG questionnaire 5 (13.5) 4 (25.0) 4 (33.3) 4 (33.3)
Self–designed questionnaire 10 (27) 1 (6.3) 0 (0.0) 0 (0.0)
Questionnaire based on ILAE/CMA/ BNI 
diagnosis
7 (18.9) 2 (12.5) 1 (8.3) 1 (8.3)
Not specified 1 (2.7) 0 (0.0) 0 (0.0) 0 (0.0)
Diagnosis of epilepsy:
By neurologists 27 (73.0) 12 (75.0) 9 (75.0) 10 (83.3)
By trained physicians 6 (16.2) 3 (18.8) 2 (16.7) 2 (16.7)
By trained investigators 2 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
Not specified 2 (5.4) 1 (6.3) 1 (8.3) 0 (0.0)
LTE – lifetime epilepsy, AE – active epilepsy, WHO – World Health Organization, ICBERG – International Community–based Epi-
lepsy Research Group, ILAE – International League Against Epilepsy, CMA – Chinese Medical Association, BNI – Beijing Neurosur-
gical Institute
Figure 1. PRISMA flow diagram. *Note: *Reason 1–Papers that were not population–based epilepsy study; *Reason 
2–Studies that were not based in Mainland China; *Reason 3–Papers with no numerical prevalence measure of 
epilepsy; *Reason 4–Studies with no clear time period; *Reason 5–Studies only reported febrile convulsions or 
provoked seizures; *Reason 6–Multiple publications of the same study; *Reason 7–Studies only reported specific 
subtype of epilepsy; *Reason 8–Unclear prevalence type.
Figure 1
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tional Community–based Epilepsy Research Group [ICBERG]). For more details of the studies, see Table 
S2 in the Online Supplementary Document.
Estimates of LTE prevalence and number of cases in China
The 37 studies that reported LTE prevalence involved a combined total of 2 851 219 participants. Of these, 
5813 met the criteria for LTE diagnosis, giving an LTE prevalence of 2.04‰. A total of 274 specific data 
points based on age, gender and location provided the information on LTE prevalence. Based on these 
informative data points, the gender–specific relationship between age and LTE prevalence was explored 
and it is shown in Figure 2. Generally, the larger studies yielded lower LTE prevalence in both males and 
females across most of the age spectrum.
In the univariate meta–regression analysis (Table S3 in Online Supplementary Document), no gender 
difference was found in LTE prevalence, whereas age and study year were all significantly associated with 
LTE prevalence. The final formula generated from the multilevel mixed–effects meta–analysis is shown 
below:
ln . . . . .odds year age age a       106 597 0 050 0 032 1 0 081 2 0 146* * * * ge age3 0 058 4 . *
Where:
odds = p/(1–p), p indicates the prevalence of LTE
year = calendar year
age1–age4 are variables created in the process of fitting cubic splines (knots: 4.5, 24.5, 45.0, 54.5, 74.5)
Based on the final regression model, age–specific LTE prevalence in mainland China was calculated for 
the years 1990, 2000 and 2015 (Table 2 and Figure 3). In 1990, the prevalence of LTE was lowest in 
the 0–4 age group (1.31‰; 95% CI = 0.85–2.00) and highest in the 30–34 age group (2.42‰; 95% 
CI:1.60–3.65). By 2015, this prevalence had increased by three–fold to 4.57‰ (95% CI = 2.52–8.27) in 
the 0–4 age group and 8.43‰ in the 30–34 age group (95% CI = 4.71–15.04). Over 25 years, the overall 
LTE prevalence had steadily increased by 259%, from 1.99‰ (95% CI = 1.31–3.02) in 1990 to 7.15‰ 
(95% CI = 3.98–12.82) in 2015. This rate of increase is similar across the entire age spectrum, fluctuating 
around 250%.
The estimated number of individuals with LTE in China was 2.30 million (95% CI = 1.51–3.49) in 1990, 
and 9.84 million (95% CI = 5.48–17.64) in 2015, which implied an overall increase of 328% throughout 
this period (Table 2 and Figure 4). The most significant increase of LTE cases was observed among peo-
Figure 2. Age–specific prevalence of lifetime epilepsy (LTE) in China based on the data points from the included 
studies. Note: The size of each bubble is proportional to the sample size, the regression lines are based on the 
retained data points.
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Table 2. Estimated age–specific prevalence of and numbers of people with lifetime epilepsy (LTE) in China in the years 1990, 2000 
and 2015, and the rate of change from 1990 to 2015 by age group
prevaLenCe of Lte (‰) number of Lte Cases (thousands) rate of Change  
(1990–2015) for:
Age 
(years)
1990 2000 2015 1990 2000 2015 Preva-
lence  
(in %)
Number 
of cases 
(in %)
0–4 1.31 
(0.85–2.00)
2.16 
(1.60–2.90)
4.57 
(2.52–8.27)
173.05  
(113.00–264.94)
172.13  
(127.74–231.91)
380.15  
(209.75–687.84)
+250 +119
5–9 1.53 
(1.00–2.32)
2.52 
(1.89–3.36)
5.34 
(2.96–9.60)
155.95  
(102.60–236.98)
270.71  
(203.15–360.67)
419.97  
(233.14–755.10)
+250 +169
10–14 1.77 
(1.17–2.69)
2.93 
(2.21–3.88)
6.20 
(3.45–11.12)
174.30  
(114.97–264.15)
383.76  
(289.21–509.10)
466.92  
(259.90–837.01)
+250 +168
15–19 2.02 
(1.33–3.07)
3.34 
(2.52–4.43)
7.07 
(3.94–12.67)
249.43  
(164.44–378.22)
338.96  
(255.33–449.87)
558.11  
(310.78–999.76)
+249 +124
20–24 2.24 
(1.48–3.40)
3.70 
(2.78–4.91)
7.82 
(4.36–14.00)
288.19  
(189.85–437.31)
360.06  
(271.02–478.21)
830.20  
(462.40–1486.46)
+249 +188
25–29 2.38 
(1.57–3.60)
3.92 
(2.96–5.20)
8.30 
(4.63–14.83)
249.27  
(164.43–377.73)
478.13  
(360.75–633.51)
1071.19 
(597.59–1914.55)
+249 +329
30–34 2.42 
(1.60–3.65)
3.99 
(3.02–5.26)
8.43 
(4.71–15.04)
205.79  
(136.04–311.18)
506.37  
(383.40–668.57)
837.98  
(468.43–1494.68)
+249 +307
35–39 2.37 
(1.57–3.58)
3.91 
(2.97–5.16)
8.28 
(4.63–14.76)
208.14  
(137.67–314.55)
404.40  
(306.56–533.29)
788.56  
(441.14–1405.54)
+249 +278
40–44 2.27 
(1.50–3.43)
3.75 
(2.84–4.94)
7.93 
(4.44–14.14)
142.97  
(94.56–216.08)
313.54  
(237.73–413.40)
944.93  
(528.69–1684.21)
+249 +560
45–49 2.14 
(1.42–3.24)
3.54 
(2.68–4.66)
7.49 
(4.19–13.34)
104.03  
(68.84–157.15)
302.62  
(229.67–398.62)
924.81  
(517.65–1647.94)
+249 +789
50–54 2.02 
(1.33–3.06)
3.33 
(2.52–4.41)
7.05 
(3.94–12.59)
91.45  
(60.35–138.54)
201.68  
(152.44–266.74)
700.89  
(391.51–1251.68)
+249 +666
55–59 1.93 
(1.27–2.94)
3.19 
(2.39–4.25)
6.75 
(3.76–12.10)
78.90  
(51.83–120.07)
145.26  
(109.05–193.44)
532.83  
(296.59–954.95)
+249 +575
60–64 1.89 
(1.24–2.88)
3.12 
(2.34–4.17)
6.61 
(3.67–11.86)
61.42  
(40.29–93.58)
127.25  
(95.33–169.81)
514.26  
(285.89–922.86)
+249 +737
65–69 1.88 
(1.23–2.87)
3.11 
(2.32–4.16)
6.58 
(3.65–11.83)
46.17  
(30.22–70.50)
105.87  
(79.04–141.76)
336.59  
(186.75–605.22)
+250 +629
70–74 1.89 
(1.23–2.92)
3.12 
(2.30–4.24)
6.62 
(3.64–11.98)
35.68  
(23.13–55.01)
74.30  
(54.68–100.93)
223.30  
(122.97–404.51)
+250 +526
75–79 1.91 
(1.21–3.01)
3.15 
(2.25–4.41)
6.68 
(3.62–12.29)
21.30  
(13.52–33.53)
45.91  
(32.82–64.19)
161.31  
(87.46–296.77)
+250 +657
80+ years 1.94 
(1.18–3.19)
3.20 
(2.15–4.75)
6.77 
(3.53–12.95)
13.83 
(8.41–22.77)
38.51  
(25.92–57.26)
151.44  
(79.00–289.61)
+250 +995
Total 1.99 
(1.31–3.02)
3.36 
(2.53–4.47)
7.15 
(3.98–12.82)
2299.87  
(1514.15–3492.29)
4269.45  
(3213.85–5671.27)
9843.44  
(5479.62–17638.67)
+259 +328
Figure 3. Age–specific prevalence of lifetime epilepsy (LTE) in China in the years 1990, 2000 and 2015, with 95% 
confidence intervals.
Figure 3
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ple aged 40 years and above, where the rates of 
change were all above 500%, and the highest was 
noted in people aged 80+ years. Most LTE cases were 
in individuals aged 20–24 years in 1990, and then 
shifted to the group of 25–29 years in 2015.
Estimates of AE prevalence and 
number of cases in China
As shown in Figure 5, the pooled 1–year AE preva-
lence across all time periods was 3.79‰ (95% 
CI = 3.31–4.34), and the 2–year and 5–year AE preva-
lence were slightly higher, as expected, amounting to 
4.08‰ (95% CI = 3.41–4.89) and 4.19‰ (95% 
CI = 3.42–5.15) respectively. When these estimates are 
applied to the Chinese population size in the year 
2015, the numbers of individuals with 1–year, 2–year 
and 5–year AE cases were estimated to 5.22 million 
(95% CI = 4.55–5.97), 5.61 million (95% CI = 4.69–
6.73) and 5.77 million (95% CI = 4.71–7.09), ac-
counting for more than half of all the contemporary 
LTE cases.
DISCUSSION
This study describes a comprehensive estimate of the 
prevalence of epilepsy in China from 1990 to 2015. 
Although this is the second attempt to summarize the 
available data on epilepsy prevalence in China, our 
study is the first (to the best of our knowledge) that 
provides robust estimates of LTE prevalence across 
the entire age range. It also reveals the prevalence of 
1–year, 2–year and 5–year AE simultaneously in Chi-
nese population. This is of particular clinical and 
public health interest, because individuals with AE 
may benefit more from treatment compared to those 
with LTE [10,33]. In addition, we also conducted a 
temporal analysis of LTE burden in China from 1990 
to 2015. This innovative exploration is of potential 
Figure 4. Estimated numbers of 
people with lifetime epilepsy (LTE) 
in China by year and age group.
Figure 5. Pooled prevalence of 1–year, 2–year and 5–year active 
epilepsy (AE) in China by random–effects meta–analysis.
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value in studying the effect of previous national antiepileptic programs. Significant strengths of this study 
include exhaustive search strategy, attempts to reduce bias by rigorous study selection procedure, parallel 
review and extraction of data.
In the current study, LTE was defined as “at least two unprovoked (or reflex) seizures, except for febrile 
convulsion and seizure induced by acute brain diseases at some point during lifetime”. Our study revealed 
LTE prevalence of 1.99‰ in 1990 and 7.15‰ in 2015 in China. Our estimate of LTE prevalence for the 
year 1990 was in line with the estimates presented in the previous systematic review, which reported a 
prevalence of 1.84‰ for the period of 1986–1990, and 3.58‰ for the period of 1991–1995 respective-
ly [19]. Our estimate of LTE prevalence in 2015 was higher than their estimate for the period from 2006–
2010 (7.15 ‰ vs 6.62‰), which is plausible given that a dramatic increase of LTE prevalence was en-
countered in our study.
When we perform comparisons to the global estimate of LTE prevalence, our estimate of LTE prevalence 
for the year 2015 (7.15‰) was even lower than the lower band of the estimated range in LMICs (8.75‰, 
95% CI = 7.23–10.59]) but equal to the upper band of that in HICs; 5.18‰, 95% CI = 3.75–7.15) 
[16,24,38]. Similarly, our estimate of 5–year AE (4.19‰) is much more in line with the estimate in de-
veloped countries (4.9‰, 95% CI = 2.3–10.3), but less than in developing countries [10]. Despite the 
higher rates of spontaneous remission of epilepsy cases, given that fact that epilepsy is still a highly stig-
matising disorder in China, any concealment could make these estimates even higher [26,39].
Epilepsy is known to affect people of all ages, though more frequently affecting young people [40]. The 
estimates in our study indicated that the LTE prevalence peaked at individuals aged 30–34 years. This 
finding confirms the statement made in previous studies that the epilepsy is generally a disease of the 
young [23]. The peak of this disorder in young age could partly be explained by the accumulation of ear-
ly–onset epilepsy cases. It is estimated that the incidence of epilepsy is the highest in young children and 
elderly, forming a characteristic U–shape [21,41]. In addition, individuals with epilepsy may at a higher 
risk of premature death. Two previous studies reported that the risk of premature death in individuals 
with epilepsy is 3–5 times higher than in general population, and especially among the young [42,43]. 
According to the survival effects theory, it is plausible that the lifetime prevalence of epilepsy showed a 
decreasing trend after the age of 30–34 years in our study. This phenomenon has also been seen in many 
other neurological diseases [44].
The gender difference is another interesting topic in epilepsy research, both relevant to the public health 
and clinical research. Previous investigations reported slightly higher prevalence estimates of epilepsy in 
males than in females, which was probably attributable to the inherent differences in healthy brain devel-
opment between genders and marked social effects on disease risks and courses [19,45,46]. However, in 
our analysis, the difference of LTE prevalence between sexes was not statistically significant. This finding 
is in contrast with the previous systematic review of epilepsy prevalence in China, but in line with the 
synthesised results in Asia, Latin America and Europe and the whole globe [21,23,24,47]. These incon-
sistencies with other studies may be a result of the different proportional contribution of epilepsy sub-
types to the included case series. According to previous evidence, localization–related symptomatic epi-
lepsy was more prevalent in males, and cryptogenic localization–related epilepsy was more prevalent in 
females [46,48].
In this study, we confirmed the hypothesis that the prevalence of LTE was continually increasing by pre-
senting a positive temporal trend between 1990 and 2015. The prevalence of LTE is determined by the 
incidence rate at which new cases arise and the mortality rate [10]. Given the increased life expectancy 
and rapid ageing process in China during the two decades, it is reasonable to expect a dramatic increase 
rate of LTE prevalence through cumulative effects [49,50].
In the current study, we developed an estimate of the 1–year, 2–year and 5–year AE prevalence in China, 
which provides a basis for future studies, especially in the research of treatment gap for epilepsy in China 
[33,34]. However, because of the scarcity of studies that reported age– or gender–specific AE prevalence, 
we were not able to undertake some more detailed studies. Compared to the global 1–year AE prevalence 
(4.6‰ in 2000 and 4.5‰ in 2000) [15] in the Campaign Against Epilepsy Demonstration Project conduct-
ed in rural China, our study revealed a much lower 1–year AE prevalence of 3.79‰ in general population.
The magnitude of epilepsy burden in China, estimated in this study, represents a huge and significant 
health and socioeconomic burden [34,51]. With proper antiepileptic medication, up to 70% of epileptic 
seizures can be well controlled [52,53]. However, previous studies suggested that more than half of the 
individuals with epilepsy in China had never been treated with appropriate antiepileptic medicines 
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[15,39]. Many barriers may contribute to this situation. In China, due to the stigma–attached nature of 
the diagnosis of epilepsy, individuals with epilepsy are generally socially isolated and suffer in silence [15, 
39]. Individuals with epilepsy are more likely to be under–educated or under–employed. A lack of knowl-
edge about the nature of epilepsy and treatment may also influence the patients’ personal health–seeking 
behaviours and compliance [15]. In addition, most individuals with epilepsy may be economically dis-
advantaged, which makes the free provision of antiepileptic medicines critically important for the man-
agement of epilepsy. However, this goal has not been universally achieved across the whole country, es-
pecially in resource–poor areas [52]. To make the situation worse, the lack of electroencephalogram and 
neuroimaging equipment, and personnel with neurologic expertise, may severely restrict the diagnosis of 
patients to a large extent.
Our study also had several potential limitations. First, our estimate of epilepsy prevalence was based on 
cross–sectional studies in the community. However, because of the uncertainty regarding each case defi-
nition, and the ratio between sensitivity and specificity of the diagnostic tools used, it has already been 
pointed that cross–sectional assessment may considerably underestimate the prevalence [44,54,55]. In 
addition, the initial suspicion on epilepsy in most of our included studies was established through the 
use of questionnaires or interviews. Although it was later also confirmed by neurologists, this investiga-
tory approach may still be problematic due to recall bias and a high proportion of concealment [15,39]. 
Second, large variations were observed between the studies included in our systematic analysis. We tried 
to minimise these variations through strict inclusion and exclusion criteria. Still, variations in study meth-
ods, approaches to sampling, diagnostic criteria, availability of or access to appropriate treatment led to 
a considerable variation. Third, our modelled estimates were based on a limited number of covariates that 
were available in our included studies. Future attempts at evidence synthesis should include more of these 
covariates, such as the subtype of epilepsy, level of economic development and treatment gap. With these 
limitations in mind, the estimates presented in this study need to be interpreted cautiously.
The results of our meta–analysis have both academic and public health implications. An immense deficit 
in epidemiologic data regarding age–specific AE prevalence and LTE prevalence in China was identified. 
In particular, new studies should also adopt appropriate methods to reduce the variation in reported 
prevalence. Other important contributors include identifying subtypes of epilepsy and the current barri-
ers in the society and health care systems. From the public health perspective, it is well–documented that 
most epilepsy cases can be prevented by effective measurements. Common preventable causes in children 
include infectious diseases, prenatal and perinatal central nervous system damage [2,16]. Birth asphyxia 
and febrile seizures are also well–documented risk factors for epilepsy. Programs targeted at reducing birth 
asphyxia and timely treatment of febrile convulsions can also contribute to the reduction of epilepsy bur-
den [56,57]. In adults, the most prevalent causes of epilepsy include head injury, intracranial infection 
and cerebrovascular diseases, which account for 88.5% of all the adult–onset epilepsy cases [58,59], high-
lighting the importance of preventing injury.
CONCLUSIONS
Our study provides a comprehensive evidence synthesis of LTE and AE prevalence in China to date. LTE 
prevalence is the highest in individuals aged 30–34 years. The burden of LTE in China has increased dra-
matically between 1990 and 2015, when the prevalence of LTE has more than doubled, and the number of 
people with LTE more than tripled. The large amount of AE cases in China calls for optimal management 
and treatment. More high–quality epidemiological studies on LTE and AE prevalence are still needed.
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